These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 11732644

  • 1. Bisphosphonates: an overview with special reference to alendronate.
    Vasikaran SD.
    Ann Clin Biochem; 2001 Nov; 38(Pt 6):608-23. PubMed ID: 11732644
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Bisphosphonates in the treatment of disorders of mineral metabolism.
    Singer FR, Minoofar PN.
    Adv Endocrinol Metab; 1995 Nov; 6():259-88. PubMed ID: 7671099
    [Abstract] [Full Text] [Related]

  • 4. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
    Plosker GL, Goa KL.
    Drugs; 1994 Jun; 47(6):945-82. PubMed ID: 7521833
    [Abstract] [Full Text] [Related]

  • 5. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
    Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S.
    J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Bisphosphonates and primary hyperparathyroidism.
    Rodan GA.
    J Bone Miner Res; 2002 Nov; 17 Suppl 2():N150-3. PubMed ID: 12412793
    [Abstract] [Full Text] [Related]

  • 10. Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone.
    Adami S, Zamberlan N, Mian M, Dorizzi R, Rossini M, Braga B, Gatti D, Bertoldo F, Locascio V.
    Bone Miner; 1994 May; 25(2):75-82. PubMed ID: 8086853
    [Abstract] [Full Text] [Related]

  • 11. Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
    Fitton A, McTavish D.
    Drugs; 1991 Feb; 41(2):289-318. PubMed ID: 1709854
    [Abstract] [Full Text] [Related]

  • 12. Ibandronate.
    Dooley M, Balfour JA.
    Drugs; 1999 Jan; 57(1):101-8; discussion 109-10. PubMed ID: 9951955
    [Abstract] [Full Text] [Related]

  • 13. Bisphosphonates: preclinical aspects and use in osteoporosis.
    Fleisch HA.
    Ann Med; 1997 Feb; 29(1):55-62. PubMed ID: 9073324
    [Abstract] [Full Text] [Related]

  • 14. Bisphosphonates use in children.
    Sebestyen JF, Srivastava T, Alon US.
    Clin Pediatr (Phila); 2012 Nov; 51(11):1011-24. PubMed ID: 22935217
    [Abstract] [Full Text] [Related]

  • 15. Bisphosphonates: mechanism of action and role in clinical practice.
    Drake MT, Clarke BL, Khosla S.
    Mayo Clin Proc; 2008 Sep; 83(9):1032-45. PubMed ID: 18775204
    [Abstract] [Full Text] [Related]

  • 16. Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy.
    Li B, Ling Chau JF, Wang X, Leong WF.
    J Cell Biochem; 2011 May; 112(5):1229-42. PubMed ID: 21465521
    [Abstract] [Full Text] [Related]

  • 17. Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission.
    Stuckey BG, Lim EM, Kent GN, Ward LC, Gutteridge DH.
    J Bone Miner Res; 2001 Sep; 16(9):1719-23. PubMed ID: 11547843
    [Abstract] [Full Text] [Related]

  • 18. [Bisphosphonates. A neu therapy principle in calcium and bone metabolism disorders].
    Raue F.
    Internist (Berl); 1999 Apr; 40(4):448-55. PubMed ID: 10354947
    [No Abstract] [Full Text] [Related]

  • 19. Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy.
    Fraser WD, Logue FC, Gallacher SJ, O'Reilly DS, Beastall GH, Ralston SH, Boyle IT.
    Bone Miner; 1991 Feb; 12(2):113-21. PubMed ID: 1849762
    [Abstract] [Full Text] [Related]

  • 20. Bisphosphonate use in conditions other than osteoporosis.
    Silverman SL.
    Ann N Y Acad Sci; 2011 Feb; 1218():33-7. PubMed ID: 20946575
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.